FDA To Name IoM Safety Review Committee Members April 18

The committee will then begin work on a safety study, which is expected to take approximately two years, agency officials say at FDA Science Board meeting. FDA also provides update on other safety initiatives – CDER Acting Deputy Director Throckmorton will chair agency’s Drug Safety Oversight Board.